The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

The US Food and Drug Administration (FDA) has approved a new presentation of Alvotech and Teva Pharmaceuticals’ SELARSDI (ustekinumab-aekn), expanding its label to include the treatment of ...

Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab), is expanded to the indications to include treatment of Crohn disease ...

The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

Alvotech (ALVO) has released an update. Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for a new intravenous presentation of ...

The remaining proceeds from the term loan are intended to support working capital needs and ongoing and near-term product launches, particularly for Simlandi and Selarsdi. Analysts maintain a ...

The remaining proceeds from the term loan are intended to support working capital needs and ongoing and near-term product launches, particularly for Simlandi and Selarsdi. Analysts maintain a positive ...

“We are thrilled with the expansion of Selarsdi’s indications, marking another significant milestone in Teva’s commitment to increasing access to biosimilars in the US,” said Thomas Rainey, Senior ...